Scholarlink

Objective <p>Alterations to the respiratory microbiota may contribute to lung cancer progression. This study examined real-world data to characterize sputum microbiota alterations and to assess their association with oncogenomic changes and response to targeted therapies in patients with lung cancer.</p> Method <p>A total of 724 patients with lung cancer who underwent etiological examinations of their sputum were retrospectively included. Tumor tissues of 105 patients were analyzed using commercial next-generation sequencing (NGS) panels targeting 1021 genes for the initial screening stage. Amplification-refractory mutation system-polymerase chain reaction was then used to assess the presence of <i>EGFR</i> mutations in 316 cases in the second stage.</p> Results <p><i>TP53</i> mutations were the most frequently observed coexisting mutations with microbial infections. In contrast, <i>EGFR</i> mutations were commonly found in patients without microbial infections. Tumor tissues of infected patients exhibited a significantly higher level of tumor mutation burden (TMB) and a greater frequency of copy number variations, especially on chromosome 11. Specifically, <i>Klebsiella pneumoniae</i> infection was more frequently associated with cases carrying <i>TP53</i> mutations; while <i>Candida albicans</i> and <i>Pseudomonas aeruginosa</i> infections were observed exclusively in cases with <i>EGFR</i> mutations. <i>EGFR</i> mutations without concurrent microbial infections were associated with a better objective response rate to EGFR tyrosine kinase inhibitors and survival benefits in patients.</p> Conclusions <p>We demonstrated that opportunistic pathogens exhibited higher infection rates in patients with <i>TP53</i>-mutated, TMB-H, and non-<i>EGFR</i>-mutated tumors. Microbial infection in patients with <i>EGFR</i> mutations might be an influencing factor that weakens the therapeutic efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A real-world evidence of sputum microbiota alterations and their association with oncogenomic changes and response to targeted therapies in patients with lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月30日

查看全文
  • Ting Li,
  • Zu-Lu Ye,
  • Xin-Hua Yang,
  • Cai-Yun He,
  • Wen-Na Xu

摘要

Objective

Alterations to the respiratory microbiota may contribute to lung cancer progression. This study examined real-world data to characterize sputum microbiota alterations and to assess their association with oncogenomic changes and response to targeted therapies in patients with lung cancer.

Method

A total of 724 patients with lung cancer who underwent etiological examinations of their sputum were retrospectively included. Tumor tissues of 105 patients were analyzed using commercial next-generation sequencing (NGS) panels targeting 1021 genes for the initial screening stage. Amplification-refractory mutation system-polymerase chain reaction was then used to assess the presence of EGFR mutations in 316 cases in the second stage.

Results

TP53 mutations were the most frequently observed coexisting mutations with microbial infections. In contrast, EGFR mutations were commonly found in patients without microbial infections. Tumor tissues of infected patients exhibited a significantly higher level of tumor mutation burden (TMB) and a greater frequency of copy number variations, especially on chromosome 11. Specifically, Klebsiella pneumoniae infection was more frequently associated with cases carrying TP53 mutations; while Candida albicans and Pseudomonas aeruginosa infections were observed exclusively in cases with EGFR mutations. EGFR mutations without concurrent microbial infections were associated with a better objective response rate to EGFR tyrosine kinase inhibitors and survival benefits in patients.

Conclusions

We demonstrated that opportunistic pathogens exhibited higher infection rates in patients with TP53-mutated, TMB-H, and non-EGFR-mutated tumors. Microbial infection in patients with EGFR mutations might be an influencing factor that weakens the therapeutic efficacy.